Recently, Nanjing RegeneCore Biotech Co.,Ltd(here★​δ±inafter referred to as "λ RegeneCore), a subsidiary of  YOUN™©©GY GROUP, independently develop∞ ed the bispecific nanobody drug RC14 α16 injection, which has been approved for cli∏≈&nical trials by the US Food and Drug Administrati♠λ>βon (FDA), marking the sy<λnchronization of the product's clinical d✔∏≤evelopment strategy with the inter✔®∏&national market. RC1416 is a recombinant anti hu€®♣man IL-4Ra and IL-5 single domain antibody inject ₩₹φion that has been approved for clinic ®φal trials by the Nati₩♣'onal Drug Administration on Ma↕βrch 27 this year, with additional maintenance↔ & therapy for moderate to severe ast★♦"hma as the indication.

RegeneCore is a leading innovative high-δ×tech enterprise of YOUNGY GROUP in the field₩&✘ of nanobody medic₩↑σine in China, committed to the re→♠∏ search and development of innovative bi©≥&ological drugs of nanobody technology. At pr✘₹↕esent, innovative research and develo← pment have been carried out for↓≤ autoimmune diseases, tumorsφ↔φ∏, etc., as well as res← earch on coupling dru‍"÷$gs and cell therapy products based nanobody.♦